Vasudev Bailey News Today

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

/PRNewswire/ -- Eko, a digital health company advancing heart and lung disease detection, today announced the appointment of Eric Davidson as President and...

/PRNewswire/ -- Eko, a digital health company advancing heart and lung disease detection, today announced the appointment of Eric Davidson as President and...

Synthetic biology pioneer joins team developing the next-generation, AI-driven enzyme engineering platform for a post-scarcity worldMENLO PARK, Calif.--(BUSINESS WIRE)--#AI--Aether Biomachines, a leading enzyme engineering company building a future of abundance, today announced the appointment of Austin Che to its B...

How to write cold emails to investors – lessons from 30 VCs Want to get your cold email to investors opened and read? Learn from the tips of some of the top VC investors. Timo Särkkä Fact: sending cold emails to investors can work. The proof? Factmata raised a $500,000 investment from Mark Cuban through a cold email. Mapistry turned a cold outreach into a $2.5M funding round. Talkdesk, a company with a valuation of $3 billion, got initially funded through a well-crafted cold email. But...

Published: Feb 17, 2021 SAN FRANCISCO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc. (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the completion of a $60 million financing. The proceeds will be used to advance Excision’s lead candidate, EBT-101, into a Phase 1/2 clinical trial in patients with chronic HIV infection. The financing will also support preclinical programs including EBT-10...